AKR1C1 controls cisplatin-resistance in head and neck squamous cell carcinoma through cross-talk with the STAT1/3 signaling pathway
Journal
Journal of Experimental and Clinical Cancer Research
Journal Volume
38
Journal Issue
1
Pages
245
Date Issued
2019
Author(s)
Abstract
Background: Cisplatin is the first-line chemotherapy used against most upper aerodigestive tract carcinomas. In head and neck cancer, sensitivity to cisplatin remains the key issue in treatment response and outcome. Genetic heterogeneity and aberrant gene expression may be the intrinsic factors that cause primary cisplatin-resistance. Methods: Combination of the HNSCC gene expression data and the cisplatin sensitivity results from public database. We found that aldo-keto reductase family 1 member C1 (AKR1C1) may be associated with cisplatin sensitivity in HNSCC treatment of na?ve cells. We examined the AKR1C1 expression and its correlation with cisplatin IC50 and prognosis in patients. The in vitro and in vivo AKR1C1 functions in cisplatin-resistance through overexpression or knockdown assays, respectively. cDNA microarrays were used to identify the upstream regulators that modulate AKR1C1-induced signaling in HNSCC. Finally, we used the cigarette metabolites to promote AKR1C1 expression and ruxolitinib to overcome AKR1C1-induced cisplatin-resistance. Results: AKR1C1 positively correlates to cisplatin-resistance in HNSCC cells. AKR1C1 is a poor prognostic factor for recurrence and death of HNSCC patients. Silencing of AKR1C1 not only reduced in vitro IC50 but also increased in vivo cisplatin responses and vise versa in overexpression cells. Cigarette metabolites also promote AKR1C1 expression. Transcriptome analyses revealed that STAT1 and STAT3 activation enable AKR1C1-induced cisplatin-resistance and can be overcome by ruxolitinib treatment. Conclusions: AKR1C1 is a crucial regulator for cisplatin-resistance in HNSCC and also poor prognostic marker for patients. Targeting the AKR1C1-STAT axis may provide a new therapeutic strategy to treat patients who are refractory to cisplatin treatment. ? 2019 The Author(s).
Subjects
AKR1C1; Cisplatin-resistance; HNSCC; Ruxolitinib; STATs
SDGs
Other Subjects
aldo keto reductase; aldo keto reductase family 1 member C1; cisplatin; complementary DNA; ruxolitinib; STAT1 protein; STAT3 protein; transcriptome; unclassified drug; 3 alpha-beta, 20 beta-hydroxysteroid dehydrogenase; 3alpha(or 20beta) hydroxysteroid dehydrogenase; antineoplastic agent; autacoid; caspase; cisplatin; protein kinase inhibitor; STAT1 protein; STAT1 protein, human; STAT3 protein; transcriptome; animal cell; animal experiment; animal model; animal tissue; Article; controlled study; DNA microarray; drug sensitivity; gene expression; gene knockdown; gene overexpression; gene regulatory network; gene silencing; head and neck squamous cell carcinoma; human; in vitro study; in vivo study; male; molecular interaction; mouse; nonhuman; priority journal; signal transduction; animal; apoptosis; biological model; cell survival; disease model; drug effect; drug screening; gene expression profiling; gene expression regulation; genetics; metabolism; mortality; pathology; prognosis; tumor cell line; 20-Hydroxysteroid Dehydrogenases; Animals; Antineoplastic Agents; Apoptosis; Caspases; Cell Line, Tumor; Cell Survival; Cisplatin; Disease Models, Animal; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Inflammation Mediators; Mice; Models, Biological; Prognosis; Protein Kinase Inhibitors; Signal Transduction; Squamous Cell Carcinoma of Head and Neck; STAT1 Transcription Factor; STAT3 Transcription Factor; Transcriptome; Xenograft Model Antitumor Assays
Publisher
BioMed Central Ltd.
Type
journal article